Today, The U.S. Food And Drug Administration Approved Leqembi (Lecanemab-Irmb) Via The Accelerated Approval Pathway For The Treatment Of Alzheimer'S Disease. Leqembi Is The Second Of A New Category Of Medications Approved For Alzheimer'S Disease That Target The Fundamental Pathophysiology Of The Disease. These Medications Represent An Important Advancement In The Ongoing Fight To Effectively Treat Alzheimer'S Disease."Alzheimer'S Disease Immeasurably Incapacitates The Lives Of Those Who Suffer From It And Has Devastating Effects On Their Loved Ones," Said Billy Dunn, M.D., Director Of The Office Of Neuroscience In The Fda'S Center For Drug Evaluation And Research. "This Treatment Option Is The Latest Therapy To Target And Affect The Underlying Disease Process Of Alzheimer'S, Instead Of Only Treating The Symptoms Of The Disease."Alzheimer'S Disease Is An Irreversible, Progressive Brain Disorder Affecting More Than 6.5 Million Americans That Slowly Destroys Memory And Thinking Skills And, Eventually, The Ability To Carry Out Simple Tasks. While The Specific Causes Of Alzheimer'S Are Not Fully Known, It Is Characterized By Changes In The Brain - Including Amyloid Beta Plaques And Neurofibrillary, Or Tau, Tangles - That Result In Loss Of Neurons And Their Connections. These Changes Affect A Person'S Ability To Remember And Think.Leqembi Was Approved Using The Accelerated Approval Pathway, Under Which The Fda May Approve Drugs For Serious Conditions Where There Is An Unmet Medical Need And A Drug Is Shown To Have An Effect On A Surrogate Endpoint That Is Reasonably Likely To Predict A Clinical Benefit To Patients. The Results Of A Phase 3 Randomized, Controlled Clinical Trial To Confirm The Drug'S Clinical Benefit Have Recently Been Reported And The Agency Anticipates Receiving The Data Soon.Researchers Evaluated Leqembi
